KRAS and bladder urachal carcinoma: Cha et al. recently conducted a WES series of cancers afflicting adolescents and young adults which featured only one patient with urachal carcinoma carrying a KRAS G13D mutation.[5] Both studies underscore the importance of the RAS/MAPK pathway in this disease, a finding that is prominently highlighted by our study demonstrating not only KRAS mutations but also recurrent NF1 mutations and KRAS amplifications as likely mechanisms of MAPK pathway activation.